{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T23:30:43Z","timestamp":1793403043785,"version":"4.5.0"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T00:00:00Z","timestamp":1784073600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T00:00:00Z","timestamp":1784073600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Obes"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1038\/s41366-026-02161-9","type":"journal-article","created":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T16:23:26Z","timestamp":1784132606000},"page":"2172-2184","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Vutiglabridin overcomes the GLP-1 RA-associated weight-loss plateau to achieve normal body weight"],"prefix":"10.1038","volume":"50","author":[{"given":"Hyeong Min","family":"Lee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kamindu Gayashan","family":"Marakkalage","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sang Hyo","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soonje","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jae Ho","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyung Soon","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2090-4256","authenticated-orcid":false,"given":"Sang-Ku","family":"Yoo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,15]]},"reference":[{"key":"2161_CR1","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1038\/s41573-021-00337-8","volume":"21","author":"TD M\u00fcller","year":"2022","unstructured":"M\u00fcller TD, Bl\u00fcher M, Tsch\u00f6p MH, DiMarchi RD. Anti-obesity drug discovery: advances and challenges. Nat Rev Drug Discov. 2022;21:201\u201323.","journal-title":"Nat Rev Drug Discov"},{"key":"2161_CR2","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1056\/NEJMoa2032183","volume":"384","author":"JPH Wilding","year":"2021","unstructured":"Wilding JPH, Batterham RL, Calanna S, Davies M, Van Gaal LF, Lingvay I, et al. Once-weekly semaglutide in adults with overweight or obesity. N Engl J Med. 2021;384:989\u20131002.","journal-title":"N Engl J Med"},{"key":"2161_CR3","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1056\/NEJMoa2206038","volume":"387","author":"AM Jastreboff","year":"2022","unstructured":"Jastreboff AM, Aronne LJ, Ahmad NN, Wharton S, Connery L, Alves B, et al. Tirzepatide once weekly for the treatment of obesity. N Engl J Med. 2022;387:205\u201316.","journal-title":"N Engl J Med"},{"key":"2161_CR4","doi-asserted-by":"crossref","unstructured":"Zheng Z, Zong Y, Ma Y, Tian Y, Pang Y, Zhang C, et al. Glucagon-like peptide-1 receptor: mechanisms and advances in therapy. Signal Transd Target Ther. 2024;9:234.","DOI":"10.1038\/s41392-024-01931-z"},{"key":"2161_CR5","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1056\/NEJMoa2301972","volume":"389","author":"AM Jastreboff","year":"2023","unstructured":"Jastreboff AM, Kaplan LM, Fr\u00edas JP, Wu Q, Du Y, Gurbuz S, et al. Triple\u2013hormone-receptor agonist retatrutide for obesity \u2014 a phase 2 trial. N Engl J Med. 2023;389:514\u201326.","journal-title":"N Engl J Med"},{"key":"2161_CR6","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1056\/NEJMoa2504214","volume":"393","author":"AM Jastreboff","year":"2025","unstructured":"Jastreboff AM, Ryan DH, Bays HE, Ebeling PR, Mackowski MG, Philipose N, et al. Once-monthly maridebart cafraglutide for the treatment of obesity - a phase 2 trial. N Engl J Med. 2025;393:843\u201357.","journal-title":"N Engl J Med"},{"key":"2161_CR7","doi-asserted-by":"publisher","first-page":"1","DOI":"10.26502\/aimr.0189","volume":"8","author":"L Pillarisetti","year":"2025","unstructured":"Pillarisetti L, Agrawal DK. Semaglutide: double-edged sword with risks and benefits. Arch Intern Med Res. 2025;8:1\u201313.","journal-title":"Arch Intern Med Res"},{"key":"2161_CR8","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1056\/NEJMoa2416394","volume":"393","author":"LJ Aronne","year":"2025","unstructured":"Aronne LJ, Horn DB, le Roux CW, Ho W, Falcon BL, Gomez Valderas E, et al. Tirzepatide as compared with semaglutide for the treatment of obesity. N Engl J Med. 2025;393:26\u201336.","journal-title":"N Engl J Med"},{"key":"2161_CR9","doi-asserted-by":"publisher","first-page":"e2457349","DOI":"10.1001\/jamanetworkopen.2024.57349","volume":"8","author":"PJ Rodriguez","year":"2025","unstructured":"Rodriguez PJ, Zhang V, Gratzl S, Do D, Goodwin Cartwright B, Baker C, et al. Discontinuation and reinitiation of dual-labeled GLP-1 receptor agonists among US adults with overweight or obesity. JAMA Netw Open. 2025;8:e2457349.","journal-title":"JAMA Netw Open"},{"key":"2161_CR10","doi-asserted-by":"publisher","first-page":"1553","DOI":"10.1111\/dom.14725","volume":"24","author":"JPH Wilding","year":"2022","unstructured":"Wilding JPH, Batterham RL, Davies M, Van Gaal LF, Kandler K, Konakli K, et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension. Diab Obes Metab. 2022;24:1553\u201364.","journal-title":"Diab Obes Metab"},{"key":"2161_CR11","doi-asserted-by":"publisher","first-page":"191","DOI":"10.70252\/ASAQ8961","volume":"2","author":"K Strohacker","year":"2009","unstructured":"Strohacker K, Carpenter K, McFarlin B. Consequences of weight cycling: an increase in disease risk? Int J Exerc Sci. 2009;2:191\u2013201.","journal-title":"Int J Exerc Sci"},{"key":"2161_CR12","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1016\/j.physbeh.2018.05.026","volume":"194","author":"SE Simonds","year":"2018","unstructured":"Simonds SE, Pryor JT, Cowley MA. Repeated weight cycling in obese mice causes increased appetite and glucose intolerance. Physiol Behav. 2018;194:184\u201390.","journal-title":"Physiol Behav"},{"key":"2161_CR13","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1001\/jama.2023.24945","volume":"331","author":"LJ Aronne","year":"2024","unstructured":"Aronne LJ, Sattar N, Horn DB, Bays HE, Wharton S, Lin WY, et al. Continued treatment with tirzepatide for maintenance of weight reduction in adults with obesity: the SURMOUNT-4 randomized clinical trial. JAMA. 2024;331:38\u201348.","journal-title":"JAMA"},{"key":"2161_CR14","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1016\/S0092-8674(01)00240-9","volume":"104","author":"BM Spiegelman","year":"2001","unstructured":"Spiegelman BM, Flier JS. Obesity and the regulation of energy balance. Cell. 2001;104:531\u201343.","journal-title":"Cell"},{"key":"2161_CR15","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1161\/CIRCULATIONAHA.111.087213","volume":"126","author":"JO Hill","year":"2012","unstructured":"Hill JO, Wyatt HR, Peters JC. Energy balance and obesity. Circulation. 2012;126:126\u201332.","journal-title":"Circulation"},{"key":"2161_CR16","doi-asserted-by":"publisher","first-page":"672","DOI":"10.3945\/jn.114.206029","volume":"145","author":"CC Ronveaux","year":"2015","unstructured":"Ronveaux CC, Tom\u00e9 D, Raybould HE. Glucagon-like peptide 1 interacts with ghrelin and leptin to regulate glucose metabolism and food intake through vagal afferent neuron signaling. J Nutr. 2015;145:672\u201380.","journal-title":"J Nutr"},{"key":"2161_CR17","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2021.678055","volume":"12","author":"A Marzook","year":"2021","unstructured":"Marzook A, Tomas A, Jones B. The interplay of glucagon-like peptide-1 receptor trafficking and signalling in pancreatic beta cells. Front Endocrinol. 2021;12:678055.","journal-title":"Front Endocrinol"},{"key":"2161_CR18","doi-asserted-by":"publisher","DOI":"10.1126\/science.adt0773","volume":"387","author":"Z Zhu","year":"2025","unstructured":"Zhu Z, Gong R, Rodriguez V, Quach KT, Chen X, Sternson SM. Hedonic eating is controlled by dopamine neurons that oppose GLP-1R satiety. Science. 2025;387:eadt0773.","journal-title":"Science"},{"key":"2161_CR19","doi-asserted-by":"publisher","first-page":"2459","DOI":"10.1111\/dom.13827","volume":"21","author":"OM Farr","year":"2019","unstructured":"Farr OM, Upadhyay J, Rutagengwa C, DiPrisco B, Ranta Z, Adra A, et al. Longer-term liraglutide administration at the highest dose approved for obesity increases reward-related orbitofrontal cortex activation in response to food cues: Implications for plateauing weight loss in response to anti-obesity therapies. Diab, Obes Metab. 2019;21:2459\u201364.","journal-title":"Diab, Obes Metab"},{"key":"2161_CR20","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1002\/oby.24027","volume":"32","author":"KD Hall","year":"2024","unstructured":"Hall KD. Physiology of the weight-loss plateau in response to diet restriction, GLP-1 receptor agonism, and bariatric surgery. Obesity. 2024;32:1163\u20138.","journal-title":"Obesity"},{"key":"2161_CR21","first-page":"100023","volume":"1","author":"JL Dragoo","year":"2021","unstructured":"Dragoo JL, Shapiro SA, Bradsell H, Frank RM. The essential roles of human adipose tissue: Metabolic, thermoregulatory, cellular, and paracrine effects. J Cartil Jt Preserv. 2021;1:100023.","journal-title":"J Cartil Jt Preserv."},{"key":"2161_CR22","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1038\/s42255-018-0021-8","volume":"1","author":"ET Chouchani","year":"2019","unstructured":"Chouchani ET, Kajimura S. Metabolic adaptation and maladaptation in adipose tissue. Nat Metab. 2019;1:189\u2013200.","journal-title":"Nat Metab"},{"key":"2161_CR23","doi-asserted-by":"publisher","first-page":"1168","DOI":"10.1038\/s41366-022-01090-7","volume":"46","author":"A Martin","year":"2022","unstructured":"Martin A, Fox D, Murphy CA, Hofmann H, Koehler K. Tissue losses and metabolic adaptations both contribute to the reduction in resting metabolic rate following weight loss. Int J Obes. 2022;46:1168\u201375.","journal-title":"Int J Obes"},{"key":"2161_CR24","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2025.118759","volume":"193","author":"HM Lee","year":"2025","unstructured":"Lee HM, Lee JH, Kim SH, Marakkalage KG, Hur J, Park HS, et al. Vutiglabridin ameliorates obesity by directly reducing fat mass through AMPK\/lipophagy activation in adipocytes. Biomed Pharmacother. 2025;193:118759.","journal-title":"Biomed Pharmacother"},{"key":"2161_CR25","doi-asserted-by":"publisher","first-page":"2744","DOI":"10.1111\/cts.13401","volume":"15","author":"JY Na","year":"2022","unstructured":"Na JY, Yoon DY, Yoo H, Lee S, Yu KS, Jang IJ, et al. Safety, tolerability, pharmacokinetic, and pharmacodynamic characteristics of vutiglabridin: a first-in-class, first-in-human study. Clin Transl Sci. 2022;15:2744\u201357.","journal-title":"Clin Transl Sci"},{"key":"2161_CR26","doi-asserted-by":"publisher","first-page":"2896","DOI":"10.3390\/nu15132896","volume":"15","author":"G Moschonis","year":"2023","unstructured":"Moschonis G, Trakman GL. Overweight and obesity: the interplay of eating habits and physical activity. Nutrients. 2023;15:2896.","journal-title":"Nutrients"},{"key":"2161_CR27","doi-asserted-by":"publisher","first-page":"e133429.","DOI":"10.1172\/jci.insight.133429","volume":"5","author":"S Gabery","year":"2020","unstructured":"Gabery S, Salinas CG, Paulsen SJ, Ahnfelt-R\u00f8nne J, Alanentalo T, Baquero AF. Semaglutide lowers body weight in rodents via distributed neural pathways. JCI Insight. 2020;5:e133429.","journal-title":"JCI Insight"},{"key":"2161_CR28","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1016\/j.nbd.2018.11.023","volume":"124","author":"M Bader","year":"2019","unstructured":"Bader M, Li Y, Lecca D, Rubovitch V, Tweedie D, Glotfelty E, et al. Pharmacokinetics and efficacy of PT302, a sustained-release Exenatide formulation, in a murine model of mild traumatic brain injury. Neurobiol Dis. 2019;124:439\u201353.","journal-title":"Neurobiol Dis"},{"key":"2161_CR29","doi-asserted-by":"publisher","first-page":"157","DOI":"10.3803\/EnM.2020.781","volume":"36","author":"JH Kim","year":"2021","unstructured":"Kim JH, Lee GY, Maeng HJ, Kim H, Bae JH, Kim KM, et al. Effects of glucagon-like peptide-1 analogue and fibroblast growth factor 21 combination on the atherosclerosis-related process in a type 2 diabetes mouse model. Endocrinol Metab. 2021;36:157\u201370.","journal-title":"Endocrinol Metab"},{"key":"2161_CR30","doi-asserted-by":"publisher","first-page":"3717","DOI":"10.1111\/bph.16438","volume":"181","author":"GC Shin","year":"2024","unstructured":"Shin GC, Lee HM, Kim N, Hur J, Yoo SK, Park YS, et al. Paraoxonase-2 agonist vutiglabridin promotes autophagy activation and mitochondrial function to alleviate non-alcoholic steatohepatitis. Br J Pharmacol. 2024;181:3717\u201342.","journal-title":"Br J Pharmacol"},{"key":"2161_CR31","doi-asserted-by":"publisher","first-page":"2049","DOI":"10.1038\/s41591-024-02996-7","volume":"30","author":"DH Ryan","year":"2024","unstructured":"Ryan DH, Lingvay I, Deanfield J, Kahn SE, Barros E, Burguera B, et al. Long-term weight loss effects of semaglutide in obesity without diabetes in the SELECT trial. Nat Med. 2024;30:2049\u201357.","journal-title":"Nat Med"},{"key":"2161_CR32","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/S2213-8587(22)00008-0","volume":"10","author":"T Kadowaki","year":"2022","unstructured":"Kadowaki T, Isendahl J, Khalid U, Lee SY, Nishida T, Ogawa W, et al. Semaglutide once a week in adults with overweight or obesity, with or without type 2 diabetes in an East Asian population (STEP 6): a randomised, double-blind, double-dummy, placebo-controlled, phase 3a trial. Lancet Diab Endocrinol. 2022;10:193\u2013206.","journal-title":"Lancet Diab Endocrinol"},{"key":"2161_CR33","doi-asserted-by":"publisher","first-page":"1414","DOI":"10.1001\/jama.2021.3224","volume":"325","author":"D Rubino","year":"2021","unstructured":"Rubino D, Abrahamsson N, Davies M, Hesse D, Greenway FL, Jensen C, et al. Effect of continued weekly subcutaneous semaglutide vs placebo on weight loss maintenance in adults with overweight or obesity: the STEP 4 randomized clinical trial. JAMA. 2021;325:1414\u201325.","journal-title":"JAMA"},{"key":"2161_CR34","doi-asserted-by":"publisher","DOI":"10.1016\/j.molmet.2024.101880","volume":"80","author":"E Nunn","year":"2024","unstructured":"Nunn E, Jaiswal N, Gavin M, Uehara K, Stefkovich M, Drareni K, et al. Antibody blockade of activin type II receptors preserves skeletal muscle mass and enhances fat loss during GLP-1 receptor agonism. Mol Metab. 2024;80:101880.","journal-title":"Mol Metab"},{"key":"2161_CR35","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2025.105836","volume":"118","author":"AO Carvas","year":"2025","unstructured":"Carvas AO, Leuthardt A, Kulka P, Lommi G, Hassan S, Coester B, et al. Cagrilintide lowers bodyweight through brain amylin receptors 1 and 3. eBioMedicine. 2025;118:105836.","journal-title":"eBioMedicine"},{"key":"2161_CR36","doi-asserted-by":"publisher","first-page":"4035","DOI":"10.1021\/jm058241a","volume":"49","author":"RP Nargund","year":"2006","unstructured":"Nargund RP, Strack AM, Fong TM. Melanocortin-4 receptor (MC4R) agonists for the treatment of obesity. J Med Chem. 2006;49:4035\u201343.","journal-title":"J Med Chem"},{"key":"2161_CR37","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1002\/oby.70087","volume":"34","author":"T Kim","year":"2025","unstructured":"Kim T, Pearson MJ, Hong H, Nason S, Seck K, Antipenko J, et al. Bile acid binding resins improve glucagon receptor agonist-mediated weight loss in diet-induced obese mice. Obesity. 2025;34:428\u2013438.","journal-title":"Obesity"},{"key":"2161_CR38","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1038\/s41366-023-01321-5","volume":"47","author":"B Tan","year":"2023","unstructured":"Tan B, Pan XH, Chew HSJ, Goh RSJ, Lin C, Anand VV, et al. Efficacy and safety of tirzepatide for treatment of overweight or obesity. A systematic review and meta-analysis. Int J Obes. 2023;47:677\u201385.","journal-title":"Int J Obes"},{"key":"2161_CR39","doi-asserted-by":"publisher","first-page":"1796","DOI":"10.1056\/NEJMoa2511774","volume":"393","author":"S Wharton","year":"2025","unstructured":"Wharton S, Aronne LJ, Stefanski A, Alfaris NF, Ciudin A, Yokote K, et al. Orforglipron, an oral small-molecule GLP-1 receptor agonist for obesity treatment. N Engl J Med. 2025;393:1796\u2013806.","journal-title":"N Engl J Med"},{"key":"2161_CR40","doi-asserted-by":"publisher","first-page":"1077","DOI":"10.1056\/NEJMoa2500969","volume":"393","author":"Wharton","year":"2025","unstructured":"Wharton, Lingvay S, Bogdanski I, Vale P, RDd, Jacob S, et al. Oral semaglutide at a dose of 25 mg in adults with overweight or obesity. N Engl J Med. 2025;393:1077\u201387.","journal-title":"N Engl J Med"},{"key":"2161_CR41","doi-asserted-by":"publisher","first-page":"2160","DOI":"10.1016\/S0140-6736(21)01751-7","volume":"398","author":"DCW Lau","year":"2021","unstructured":"Lau DCW, Erichsen L, Francisco AM, Satylganova A, le Roux CW, McGowan B, et al. Once-weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, double-blind, placebo-controlled and active-controlled, dose-finding phase 2 trial. Lancet. 2021;398:2160\u201372.","journal-title":"Lancet"},{"key":"2161_CR42","doi-asserted-by":"publisher","first-page":"e139160.","DOI":"10.1172\/jci.insight.139160","volume":"6","author":"C Cero","year":"2021","unstructured":"Cero C, Lea HJ, Zhu KY, Shamsi F, Tseng Y-H, Cypess AM. \u03b23-adrenergic receptors regulate human brown\/beige adipocyte lipolysis and thermogenesis. JCI Insight. 2021;6:e139160.","journal-title":"JCI Insight"},{"key":"2161_CR43","doi-asserted-by":"publisher","first-page":"1341","DOI":"10.1080\/15548627.2015.1061849","volume":"11","author":"RA Sinha","year":"2015","unstructured":"Sinha RA, Singh BK, Zhou J, Wu Y, Farah BL, Ohba K, et al. Thyroid hormone induction of mitochondrial activity is coupled to mitophagy via ROS-AMPK-ULK1 signaling. Autophagy. 2015;11:1341\u201357.","journal-title":"Autophagy"},{"key":"2161_CR44","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2458-14-371","volume":"14","author":"L Roh","year":"2014","unstructured":"Roh L, Braun J, Chiolero A, Bopp M, Rohrmann S, Faeh D. Mortality risk associated with underweight: a census-linked cohort of 31,578 individuals with up to 32 years of follow-up. BMC Public Health. 2014;14:371.","journal-title":"BMC Public Health"}],"container-title":["International Journal of Obesity"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41366-026-02161-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41366-026-02161-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41366-026-02161-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T23:01:19Z","timestamp":1793401279000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41366-026-02161-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,15]]},"references-count":44,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["2161"],"URL":"https:\/\/doi.org\/10.1038\/s41366-026-02161-9","relation":{},"ISSN":["0307-0565","1476-5497"],"issn-type":[{"value":"0307-0565","type":"print"},{"value":"1476-5497","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,15]]},"assertion":[{"value":"13 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 June 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 July 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 July 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare the following financial interests\/personal relationships which may be considered as potential competing interests: Sang-Ku Yoo has patent Pyranochromenyl phenol derivative, and pharmaceutical composition for treating metabolic syndrome or inflammatory disease issued to US9783551B2. HML, KGM, SHK, SL, JHL, HSP and S-KY are current employees of Glaceum Inc. and hold Glaceum\u2019s stocks\/shares. Glaceum Inc. holds the intellectual property rights of Vutiglabridin.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}},{"value":"All procedures involving animals at Lee Gil Ya Cancer and Diabetes Institute (Gachon University) were approved by the Institutional Animal Care and Use Committee (Approval No. LCDI-2021-0010, LCDI-2021-0042, LCDI-2021-0108; LCDI-2023-0047). The studies were conducted in accordance with local legislation and institutional requirements.","order":2,"name":"Ethics","label":"Ethics approval","group":{"name":"EthicsHeading","label":"Ethics"}}]}}